AU2013333948B2 - Antibodies to amyloid beta - Google Patents

Antibodies to amyloid beta Download PDF

Info

Publication number
AU2013333948B2
AU2013333948B2 AU2013333948A AU2013333948A AU2013333948B2 AU 2013333948 B2 AU2013333948 B2 AU 2013333948B2 AU 2013333948 A AU2013333948 A AU 2013333948A AU 2013333948 A AU2013333948 A AU 2013333948A AU 2013333948 B2 AU2013333948 B2 AU 2013333948B2
Authority
AU
Australia
Prior art keywords
amino acid
binding
antibody molecule
peptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013333948A
Other languages
English (en)
Other versions
AU2013333948A1 (en
Inventor
Maria Groves
Suzanne GUSTAVSSON
Kina Hoglund
Chris Lloyd
David LOWNE
Adrian NICKSON
Camilla NIVA
Sylvia SIMON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013333948(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2013333948A1 publication Critical patent/AU2013333948A1/en
Application granted granted Critical
Publication of AU2013333948B2 publication Critical patent/AU2013333948B2/en
Priority to AU2018256498A priority Critical patent/AU2018256498C1/en
Priority to AU2020256414A priority patent/AU2020256414B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013333948A 2012-10-15 2013-10-15 Antibodies to amyloid beta Active AU2013333948B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018256498A AU2018256498C1 (en) 2012-10-15 2018-10-30 Antibodies to amyloid beta
AU2020256414A AU2020256414B2 (en) 2012-10-15 2020-10-16 Antibodies to amyloid beta

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713996P 2012-10-15 2012-10-15
US61/713,996 2012-10-15
PCT/EP2013/071567 WO2014060444A1 (en) 2012-10-15 2013-10-15 Antibodies to amyloid beta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018256498A Division AU2018256498C1 (en) 2012-10-15 2018-10-30 Antibodies to amyloid beta

Publications (2)

Publication Number Publication Date
AU2013333948A1 AU2013333948A1 (en) 2015-05-14
AU2013333948B2 true AU2013333948B2 (en) 2018-08-02

Family

ID=49765450

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013333948A Active AU2013333948B2 (en) 2012-10-15 2013-10-15 Antibodies to amyloid beta
AU2018256498A Active AU2018256498C1 (en) 2012-10-15 2018-10-30 Antibodies to amyloid beta
AU2020256414A Active AU2020256414B2 (en) 2012-10-15 2020-10-16 Antibodies to amyloid beta

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018256498A Active AU2018256498C1 (en) 2012-10-15 2018-10-30 Antibodies to amyloid beta
AU2020256414A Active AU2020256414B2 (en) 2012-10-15 2020-10-16 Antibodies to amyloid beta

Country Status (23)

Country Link
US (6) US9834598B2 (https=)
EP (2) EP3721942A1 (https=)
JP (5) JP6343615B2 (https=)
KR (2) KR102308915B1 (https=)
CN (2) CN105164156B (https=)
AU (3) AU2013333948B2 (https=)
BR (1) BR112015008347B1 (https=)
CA (1) CA2888322A1 (https=)
CY (1) CY1122987T1 (https=)
DK (1) DK2906597T3 (https=)
ES (1) ES2802873T3 (https=)
HR (1) HRP20200936T1 (https=)
HU (1) HUE051127T2 (https=)
LT (1) LT2906597T (https=)
ME (1) ME03751B (https=)
MX (2) MX370725B (https=)
PL (1) PL2906597T3 (https=)
PT (1) PT2906597T (https=)
RS (1) RS60388B1 (https=)
RU (2) RU2689674C2 (https=)
SI (1) SI2906597T1 (https=)
SM (1) SMT202000340T1 (https=)
WO (1) WO2014060444A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2689674C2 (ru) * 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
WO2016120843A1 (en) * 2015-01-29 2016-08-04 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
JP6920293B2 (ja) 2015-10-30 2021-08-18 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ＩｇＧ軽鎖におけるＮ末端切断の防止
US20190262327A1 (en) 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
CA3026598A1 (en) * 2016-06-07 2017-12-14 Biogen International Neuroscience Gmbh Methods for treating alzheimer's disease
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CA3106116A1 (en) 2018-07-17 2020-01-23 Jiangsu Hengrui Medicine Co., Ltd. Anti-abeta antibody, antigen-binding fragment thereof and application thereof
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021011673A2 (en) * 2019-07-16 2021-01-21 Ming Jin Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
CN111454980A (zh) * 2020-04-14 2020-07-28 郑州师范学院 重组载体的构建方法及其构建的重组载体及应用
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
IL299215A (en) * 2020-06-25 2023-02-01 Medimmune Ltd Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN116716351B (zh) * 2023-03-30 2024-02-23 湖北天勤生物技术研究院有限公司 用于构建食蟹猴阿尔兹海默症模型的组合物及其应用和构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
EP1717250A1 (en) * 2004-02-20 2006-11-02 Immuno-Biological Laboratories Co., Ltd. Monoclonal antibody and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565332A (en) 1896-08-04 Toy for making soap-bubbles
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
ES2253358T3 (es) 2000-03-31 2006-06-01 Cambridge Antibody Technology Limited Mejoras en la visualizacion del ribosoma.
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP4662719B2 (ja) * 2002-04-19 2011-03-30 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント アルツハイマー病の処置のための免疫学的方法および組成物
PL1735347T3 (pl) * 2004-03-29 2013-04-30 The Univ Court Of The Univ Of Aberdeen Specyficznie wiążące cząsteczki przeciwko synaptofizynie
WO2006016644A1 (ja) * 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation 抗体及びその利用
CN101076543A (zh) * 2004-10-13 2007-11-21 阿布林克斯公司 用于治疗和诊断变性神经疾病如阿尔茨海默症的单结构域骆驼抗淀粉样蛋白β的抗体以及包含它的多肽
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
GB0500099D0 (en) 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
ES2318918B1 (es) * 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8445649B2 (en) * 2007-10-29 2013-05-21 Tao Health Life Pharma Co., Ltd. Antibody and use thereof
WO2009075084A1 (ja) * 2007-12-12 2009-06-18 Immuno-Biological Laboratories Co., Ltd. アルツハイマー病の存在又は傾向の診断薬及び診断方法
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
WO2009085200A2 (en) * 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
RU2689674C2 (ru) * 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US20190262327A1 (en) 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
AR107783A1 (es) 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
EP1717250A1 (en) * 2004-02-20 2006-11-02 Immuno-Biological Laboratories Co., Ltd. Monoclonal antibody and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. KIM ET AL, "Ab40 Inhibits Amyloid Deposition In Vivo", JOURNAL OF NEUROSCIENCE, (20070117), vol. 27, no. 3, doi:10.1523/JNEUROSCI.4849-06.2007, ISSN 0270-6474, pages 627 - 633 *
Y. LEVITES, "Anti-Ab42- and anti-Ab40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model", JOURNAL OF CLINICAL INVESTIGATION, (20051208), vol. 116, no. 1, doi:10.1172/JCI25410, ISSN 0021-9738, pages 193 - 201 *

Also Published As

Publication number Publication date
US20180105585A1 (en) 2018-04-19
KR20210125587A (ko) 2021-10-18
RU2689674C2 (ru) 2019-05-28
JP2015536645A (ja) 2015-12-24
MX2015004763A (es) 2016-01-08
CY1122987T1 (el) 2021-10-29
RU2018110064A (ru) 2019-02-28
CN110294804A (zh) 2019-10-01
JP6669805B2 (ja) 2020-03-18
US20210009665A1 (en) 2021-01-14
JP6343615B2 (ja) 2018-06-20
AU2013333948A1 (en) 2015-05-14
RS60388B1 (sr) 2020-07-31
CN105164156B (zh) 2019-04-02
AU2020256414A1 (en) 2020-11-12
HK1213906A1 (en) 2016-07-15
LT2906597T (lt) 2020-07-10
JP7301924B2 (ja) 2023-07-03
ME03751B (me) 2021-04-20
US20250304670A1 (en) 2025-10-02
AU2018256498C1 (en) 2024-06-20
BR112015008347B1 (pt) 2023-12-26
EP2906597B1 (en) 2020-04-08
AU2018256498B2 (en) 2020-07-23
AU2020256414B2 (en) 2024-01-25
KR102450670B1 (ko) 2022-10-04
EP3721942A1 (en) 2020-10-14
HRP20200936T1 (hr) 2020-09-18
ES2802873T3 (es) 2021-01-21
MX2019015602A (es) 2020-02-26
EP2906597A1 (en) 2015-08-19
AU2018256498A1 (en) 2018-11-22
DK2906597T3 (da) 2020-07-13
US12344664B2 (en) 2025-07-01
KR102308915B1 (ko) 2021-10-06
SMT202000340T1 (it) 2020-07-08
JP2022025078A (ja) 2022-02-09
JP6959377B2 (ja) 2021-11-02
US11286297B2 (en) 2022-03-29
MX370725B (es) 2019-12-20
JP2020099340A (ja) 2020-07-02
JP2023116770A (ja) 2023-08-22
US20240294619A1 (en) 2024-09-05
BR112015008347A2 (pt) 2017-12-05
US20150299299A1 (en) 2015-10-22
SI2906597T1 (sl) 2020-08-31
WO2014060444A1 (en) 2014-04-24
CA2888322A1 (en) 2014-04-24
JP2018150346A (ja) 2018-09-27
RU2015118180A (ru) 2016-12-10
HUE051127T2 (hu) 2021-03-01
CN110294804B (zh) 2023-07-14
PL2906597T3 (pl) 2020-09-21
KR20150066593A (ko) 2015-06-16
CN105164156A (zh) 2015-12-16
US9834598B2 (en) 2017-12-05
US10662239B2 (en) 2020-05-26
RU2651486C2 (ru) 2018-04-19
RU2018110064A3 (https=) 2019-02-28
PT2906597T (pt) 2020-06-18
US12098191B2 (en) 2024-09-24
US20220251181A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US12344664B2 (en) Antibodies to amyloid beta
US20190262327A1 (en) Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
HK40014502B (en) Antibodies to amyloid beta
HK1213906B (en) Antibodies to amyloid beta
HK40014502A (en) Antibodies to amyloid beta
BR122023019806B1 (pt) Molécula de anticorpo, uso de dita molécula de anticorpo, composição para uso no tratamento de uma doença associada com betaamilóide, uso de uma composição, ácido nucleico, célula hospedeira e método para produção de uma molécula de anticorpo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)